Literature DB >> 16805890

Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis.

Nigel Toussaint1, Janeane Boddington, Rosemary Simmonds, Claire Waldron, Christine Somerville, John Agar.   

Abstract

An elevated calcium x phosphate product (Ca x P) is an independent risk factor for vascular calcification and cardiovascular death in dialysis patients. More physiological dialysis in patients undergoing nocturnal hemodialysis (NHD) has been shown to produce biochemical advantages compared with conventional hemodialysis (CHD) including superior phosphate (P) control. Benefits of dialysate with greater calcium (Ca) concentration are also reported in NHD to prevent Ca depletion and subsequent hyperparathyroidism, but there are concerns that a higher dialysate Ca concentration may contribute to raised serum Ca levels and greater Ca x P and vascular disease. The NHD program at our unit has been established for 4 years, and we retrospectively analyzed Ca and P metabolism in patients undergoing NHD (8-9 h/night, 6 nights/week). Our cohort consists of 11 patients, mean age 49.3 years, who had been on NHD for a minimum of 12 months, mean 34.3 months. Commencement was with low-flux (LF) NHD and 1.5 mmol/L Ca dialysate concentration, with conversion to high-flux (HF) dialyzers after a period (mean duration 18.7 months). We compared predialysis serum albumin, intact parathyroid hormone, P, total corrected Ca, and Ca x P at baseline on CHD, after conversion to LF NHD and during HF NHD. We also prospectively measured bone mineral density (BMD) on all patients entering the NHD program. Bone densitometry (DEXA) scans were performed at baseline (on CHD) and yearly after commencement of NHD. With the introduction of HF dialyzers, the Ca dialysate concentration was concurrently raised to 1.75 mmol/L after demonstration on DEXA scans of worsening osteopenia. Analysis of BMD, for all parameters, revealed a decrease over the first 12 to 24 months (N = 11). When the dialysate Ca bath was increased, the median T and Z scores subsequently increased (data at 3 years, N = 6). The mean predialysis P levels were significantly lower on LF NHD vs. CHD (1.51 vs. 1.77 mmol/L, p = 0.014), while on HF NHD P was lower again (1.33 mmol/L, p = 0.001 vs. CHD). Predialysis Ca levels decreased with conversion from CHD to LF NHD (2.58 vs. 2.47 mmol/L, p = 0.018) using a 1.5 mmol/L dialysate Ca concentration. The mean Ca x P on CHD was 4.56 compared with a significant reduction of 3.74 on LF NHD (p = 0.006) and 3.28 on HF NHD (p = 0.001 vs. CHD), despite the higher dialysate Ca in the latter. We conclude that an elevated dialysate Ca concentration is required to prevent osteopenia. With concerns that prolonged higher Ca levels contribute to increased cardiovascular mortality, the optimal Ca dialysate bath is still unknown. Better P control on NHD, however, reduces the overall Ca x P, despite the increased Ca concentration, therefore reducing the risk of vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16805890     DOI: 10.1111/j.1542-4758.2006.00109.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  4 in total

Review 1.  Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine.

Authors:  Bernard Canaud; Stefano Stuard; Frank Laukhuf; Grace Yan; Maria Ines Gomez Canabal; Paik Seong Lim; Michael A Kraus
Journal:  Clin Kidney J       Date:  2021-12-27

2.  Low calcium dialysate combined with CaCO3 in hyperphosphatemia in hemodialysis patients.

Authors:  Zhuo Gao; Li-DE Lun; Xin-Lun Li
Journal:  Exp Ther Med       Date:  2013-04-17       Impact factor: 2.447

Review 3.  Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.

Authors:  Nigar Sekercioglu; Lehana Thabane; Juan Pablo Díaz Martínez; Gihad Nesrallah; Christopher J Longo; Jason W Busse; Noori Akhtar-Danesh; Arnav Agarwal; Reem Al-Khalifah; Alfonso Iorio; Gordon H Guyatt
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

4.  Bioimpacts of dialyzer variety on phosphorus level in Iranian hemodialysis patients.

Authors:  Aiyoub Pezeshgi; Bahareh Moharrami; Goodarz Kolifarhood; Alireza Sadeghi; Masoud Asadi-Khiavi
Journal:  J Renal Inj Prev       Date:  2016-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.